EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

The Effectiveness and Safety of Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Oligoprogressive Breast Cancer: A Systematic Review

Bernie Yan iD, Sherif Ramadan, Katarzyna J Jerzak, Alexander V Louie, Elysia Donovan

Current Oncology · 2023

DOI: 10.3390/curroncol30070505 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Current Oncology, 2023. Verfasst von Bernie Yan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Health Sciences, McMaster University, Hamilton, ON L8S 4L8, Canada. Hauptthemen laut MEDLINE: Radiosurgery, Breast Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Stereotactic body radiotherapy (SBRT) has emerged as a technique to treat oligoprogressive sites among patients with breast cancer who are otherwise doing well on systemic therapy. This study systematically reviewed the efficacy and safety of SBRT in the setting of oligoprogressive breast cancer. A literature search was conducted in the MEDLINE database. Studies regarding SBRT and oligoprogressive breast cancer were included. Key outcomes of interest were toxicity, local control, progression, and overall survival. From 863 references, five retrospective single-center cohort studies were identified. All studies included patients with both oligometastatic and oligoprogressive disease; 112 patients with oligoprogressive breast cancer were identified across these studies. Patient age ranged from 22 to 84, with a median of 55 years of age. Most patients had hormone-receptor-positive and HER2-negative disease. SBRT doses varied from 24 to 60 Gy in 1–10 fractions based on the location/size of the lesion. Forty toxicity events were reported, of which the majority (n = 25, 62.5%) were grade 1–2 events. Among 15 patients who received SBRT concurrently with a CDK4/6 inhibitor, 37.5% of patients experienced grade 3–5 toxicities. Progression-free and overall survival ranged from 17 to 57% and 62 to 91%, respectively. There are limited data on the role of SBRT in oligoprogressive breast cancer, and prospective evaluation of this strategy is awaited to inform its safety and efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RadiosurgeryBreast NeoplasmsHumansYoung AdultAdultMiddle AgedAgedAged, 80 and overFemaleRetrospective Studies

Stichwörter der Autor:innen

SBRTbreast canceroligoprogression

Autor:innen und Institutionen

  • Faculty of Health Sciences, McMaster University, Hamilton, ON L8S 4L8, Canada.
  • Department of Radiation Oncology, London Health Sciences Centre, London, ON N6A 5W9, Canada.
  • Department of Medicine, Sunnybrook Odette Cancer Centre, Toronto, ON M4N 3M5, Canada.
  • Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada.
  • Department of Radiation Oncology, Juravinski Cancer Centre, Hamilton Health Sciences, Hamilton, ON L8V 5C2, Canada.

ORCID-Profile: Bernie Yan

Zitieren

APA

Yan, B., Ramadan, S., Jerzak, K. J., Louie, A. V., & Donovan, E. (2023). The Effectiveness and Safety of Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Oligoprogressive Breast Cancer: A Systematic Review. Current Oncology. https://doi.org/10.3390/curroncol30070505

Vancouver

Yan B, Ramadan S, Jerzak KJ, Louie AV, Donovan E. The Effectiveness and Safety of Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Oligoprogressive Breast Cancer: A Systematic Review. Current Oncology. 2023. doi:10.3390/curroncol30070505

BibTeX
@article{Yan2023,
  author = {Yan, Bernie and Ramadan, Sherif and Jerzak, Katarzyna J and Louie, Alexander V and Donovan, Elysia},
  title = {The Effectiveness and Safety of Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Oligoprogressive Breast Cancer: A Systematic Review},
  journal = {Current Oncology},
  year = {2023},
  doi = {10.3390/curroncol30070505}
}
Kostenlos starten →